NCT04442230View on ClinicalTrials.gov

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

PHASE2TerminatedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 10, 2020

Primary Completion Date

February 15, 2021

Study Completion Date

February 15, 2021

Conditions
Coronavirus Infection
Interventions
BIOLOGICAL

NasoVAX

NasoVAX consists of replication-deficient adenovirus vectors in suspension

OTHER

Placebo

Normal saline

Trial Locations (7)

28303

Carolina Institute for Clinical Research, Fayetteville

30260

Infinite Clinical Trials, Morrow

33176

Miami Dade Medical Research Institute, Miami

60607

Cedar Crosse Research Center, Chicago

77057

Next Level Urgent Care, Houston

77058

Centex Studies, Houston

78504

Centex Studies, McAllen

Sponsors

Lead Sponsor

Altimmune, Inc.
All Listed Sponsors
lead

Altimmune, Inc.

INDUSTRY